Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
IPO Year:
Exchange: AMEX
Website: actiniumpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2024 | $16.00 → $2.00 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $25.00 | Overweight | Stephens |
| 9/6/2023 | $11.60 | Buy | HSBC Securities |
| 2/21/2023 | Outperform → Mkt Perform | William Blair | |
| 9/8/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 8/25/2022 | $16.00 | Buy | B. Riley Securities |
| 8/3/2021 | $57.00 → $45.00 | Buy | HC Wainwright & Co. |
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients - Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 - Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover - Iomab-B was
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,
- Full Iomab-B SIERRA data set to be presented in late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 - Company to host conference call and webcast on Saturday, February 18, 2023, at 6:00 PM EST - SIERRA trial met primary endpoint with high statistical significance (p<0.0001) - Company to host Iomab-B KOL event with Dr. Sergio Giralt of Memorial Sloan Kettering Cancer Center at 8:00 AM EST on February 28, 2023 NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as
- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001 NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a
INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors. myNEXUS delivers integrated clinical support services for approximately 1.7 million Medicare Advantage members across 20 states. “Providing timely care for members in their homes allows for both excellent personalized care as well as the comfort of being in preferred environments,” said Prakash Patel, M.D., Anthem Executive Vice President, and President, Anthem Diversified Business Group. “Bringing the right level of whole person care into the home has been de
B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously
Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00
HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60
William Blair downgraded Actinum Pharma from Outperform to Mkt Perform
Cantor Fitzgerald initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $20.00
B. Riley Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $16.00
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $45.00 from $57.00 previously
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $57.00 from $65.00 previously
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium recently completed expansion of its New York City based research facilities to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to investigate novel radiotherapy combinations with checkpoint inhibitors. Actinium has more than doubled its laboratory footprint and expanded its R&D capabilities. In addition to infrastructure, Actinium has increased its R&D team to include scientists with e
NEW YORK, March 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Mark Kubik, MBA to the position of Chief Business Officer (CBO). In this role, Mr. Kubik will be responsible for leading the Company's business development activities including collaboration and partnership activities as well as portfolio and alliance management. He will focus on leveraging Actinium's AWE technology platform, which encompasses Actinium's strong intellectual property portfolio, know-how and research capabilities, and pipeline of ARCs or antibody radiation conjugates to drive business development activity. Mark joins Actinium from OncoIm
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium's CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia ("R/R AML"). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to work
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy - Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK, May 6
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working - ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option - ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs NEW YORK, Apr
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML modelsActimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignanciesActimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCINEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceutical
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope. Initial pre
- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology - Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditioning - Actinium's targeted radiotherapy programs expanded to four multi-billion-dollar market opportunities NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:A
- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure - Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market - Presentation follows Investor KOL Event and Company Update on March 25th NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a bus
- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined - Actinium to highlight manufacturing infrastructure development activity to support
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. Targeted radiotherapies using
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and menin inhibitors to define transcriptional profiles in AML cells following treatment with these combinations. The second objective is to assess the activity of Actimab-A-based combinations on primary
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA® and OPDIVO® in solid tumor indications - Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology's hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025 - Planned pivotal Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory AML patients further supported by recent publication of results